The 2023 Foundation Research Agenda includes these items

Dr. Thomas Devlin is world-renowned for his research in acute ischemic stroke with over twenty years of experience as a vascular neurologist Currently, he is the Director of the Chattanooga-based CHI–Memorial Stroke & Neuroscience Center, part of the national organization Common Spirit.

Prior to his CHI-Memorial appointment Dr. Devlin served as the Chairman of the Department of Neurology for over 10 years at the University of Tennessee College of Medicine, Chattanooga, and is currently on faculty there as a full professor of Neurology.

As the Neurology Department Chair and Medical Director of the Clinical Program at Erlanger Health System, Dr. Devlin recruited a team of eminent stroke Neurologists and Interventional Radiologists becoming one of the largest and most highly respected stroke treatment facilities worldwide.

He is the Founder and Director of the Chattanooga Center for Neurologic Research (CCNR), a private research company, serving as well as the President and Medical Director of the NeuroScience Innovation Foundation.  As the director of CCNR, Dr. Devlin has published more than a dozen articles on acute stroke treatment and with Dr. Blaise Baxter, he authored the first single-center confirmation of the clinical benefit of advanced stroke thrombectomy procedures using the MERCI device. His center was the highest enrolling center and the center demonstrating the very best patient outcomes worldwide in the landmark SWIFT-PRIME study that proved the benefit of endovascular therapy for stroke over IV tPA.

As the director of the Chattanooga Center for Neurologic Research, Dr. Devlin has developed Erlanger hospital into a testbed center for translational research for high-tech, cutting-edge, stroke treatments in partnership with biotech companies from around the world. Dr. Devlin has been a Principal Investigator on over 60 major clinical trials of new thrombolytic, neuroprotectant, stem-cell, and device therapies for acute stroke. He currently serves as the national principal investigator for the LUMOSA trial of a novel thrombolytic medication. In partnership with Dr. Peter Hunt, an otolaryngologist from Chattanooga, he helped pioneer the use of the Brainsgate surgical device, and its telemedicine-based navigation system, for intracranial arterial dilation in acute stroke patients. And as the director of the leading American site in the Brainsgate trial, the technology is now pending full FDA approval. More recently, Dr. Devlin has been instrumental in the FDA approval of two new artificial intelligence-based technologies: Viz.ai and NovaSignal. Dr. Devlin was the lead clinician in the development of these technologies and his center was the first hospital to acquire both technologies once fully commercialized. He is now the national principal investigator on the DISTINCTION trial designed to prove the clinical benefit of Viz.ai.

Dr. Devlin is founder and currently the Medical Director of the Neuroscience Innovation Foundation, a medical nonprofit corporation supporting research and clinical care in Neuroscience.

Previously, Dr. Devlin was the Founder of the non-profit Pleiades Foundation for Advanced Neuro-Medical Education which provided medical education to physicians and administrators throughout the world on both the clinical and financial aspects of stroke center development. The activities of the Pleiades Foundation were assumed by Erlanger Health System in 2016.

Dr. Devlin served as the National Program Co-Chair of the International Society for Vascular and Interventional Neurology in 2017 and 2018 and was awarded a fellowship from that society.

Thomas Devlin earned his medical degree from Baylor College of Medicine in 1991, completed a residency in Neurology at Duke University in 1995, and a fellowship in neurocritical care at the University of Virginia in 1996 with the father of neurocritical care, Dr. Thomas Bleck.